- Home
- RMTI vs ANL Comparison
RMTI vs ANL Comparison
Compare RMTI & ANL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | RMTI | ANL |
|---|---|---|
| Founded | 1994 | 2004 |
| Country | United States | Cayman Islands |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 35.1M | 52.0M |
| IPO Year | 1998 | 2023 |
Fundamental Metrics
Financial Performance| Metric | RMTI | ANL |
|---|---|---|
| Price | $0.84 | $1.60 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $2.50 | N/A |
| AVG Volume (30 Days) | ★ 227.0K | 28.5K |
| Earning Date | 11-12-2025 | 04-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $75,577,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $8.12 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.78 | $0.88 |
| 52 Week High | $2.41 | $2.99 |
Technical Indicators
Market Signals| Indicator | RMTI | ANL |
|---|---|---|
| Relative Strength Index (RSI) | 35.10 | 61.06 |
| Support Level | $0.87 | $0.88 |
| Resistance Level | $0.97 | $1.59 |
| Average True Range (ATR) | 0.06 | 0.18 |
| MACD | -0.00 | 0.04 |
| Stochastic Oscillator | 3.47 | 92.82 |
Price Performance
Historical ComparisonAbout RMTI Rockwell Medical Inc.
Rockwell Medical Inc is a healthcare company that develops, manufactures, commercializes, and distributes a portfolio of hemodialysis products for dialysis providers. It is a supplier of liquid bicarbonate concentrates, and acid and dry bicarbonate concentrates for dialysis patients in the United States. The company's products include CitraPure citric acid concentrate, RenalPure liquid acid concentrate, and SteriLyte bicarbonate concentrate among others.
About ANL Adlai Nortye Ltd.
Adlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.